![Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors’ reply]()
Editorial: antigenic response to CT-P13 and infliximab originator in IBD shows similar epitope recognition-evidence from basic science supports safe switching to biosimilars. Authors’ replyGoncalves, J.; Magro, F.; Danese, S.; Lakatos, P. L.; Ben-Horin, S. · Alimentary Pharmacology & Therapeutics · 2018